Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D trimmed its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 61,270 shares of the biopharmaceutical company’s stock after selling 156 shares during the period. State of New Jersey Common Pension Fund D owned 0.06% of Regeneron Pharmaceuticals worth $53,813,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also made changes to their positions in REGN. Annis Gardner Whiting Capital Advisors LLC acquired a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth $26,000. Fortitude Family Office LLC purchased a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $31,000. MCF Advisors LLC increased its position in shares of Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 12 shares in the last quarter. Criterion Capital Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $37,000. Finally, Sutton Wealth Advisors Inc. boosted its position in shares of Regeneron Pharmaceuticals by 38.2% in the 3rd quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 13 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN traded down $7.48 during trading on Friday, hitting $883.20. 505,575 shares of the stock were exchanged, compared to its average volume of 491,077. The company has a market cap of $96.94 billion, a PE ratio of 25.63, a P/E/G ratio of 2.60 and a beta of 0.11. The company has a current ratio of 5.69, a quick ratio of 4.94 and a debt-to-equity ratio of 0.10. The company has a fifty day moving average price of $949.30 and a two-hundred day moving average price of $893.27. Regeneron Pharmaceuticals, Inc. has a 12-month low of $684.80 and a 12-month high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, topping analysts’ consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The company had revenue of $3.43 billion for the quarter, compared to the consensus estimate of $3.29 billion. During the same period in the previous year, the business earned $10.96 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up .6% compared to the same quarter last year. On average, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 38.8 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. StockNews.com cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, April 20th. Barclays increased their price target on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 23rd. Bank of America lifted their price objective on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research note on Friday, April 12th. Cantor Fitzgerald reiterated a “neutral” rating and set a $925.00 target price on shares of Regeneron Pharmaceuticals in a research note on Monday, April 15th. Finally, Morgan Stanley raised their price target on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a report on Wednesday, March 13th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $977.77.

Insider Activity at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $954.22, for a total value of $95,422.00. Following the sale, the director now directly owns 18,382 shares in the company, valued at $17,540,472.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $954.22, for a total value of $95,422.00. Following the sale, the director now directly owns 18,382 shares in the company, valued at $17,540,472.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Bonnie L. Bassler sold 854 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $979.25, for a total value of $836,279.50. Following the sale, the director now owns 1,382 shares of the company’s stock, valued at approximately $1,353,323.50. The disclosure for this sale can be found here. In the last three months, insiders have sold 11,022 shares of company stock valued at $10,552,991. Insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.